OR WAIT 15 SECS
The company is investing approximately $14 million to expand biologics packaging capabilities and capacity at its biologics manufacturing facility in Bloomington, IN.
On Dec. 3, 2018, Catalent Pharma Solutions announced that it is investing approximately $14 million to expand biologics packaging capabilities and capacity at its Bloomington, IN, biologics manufacturing facility.
The company reports that construction is expected to be completed in February 2019, with installation and commissioning of new equipment to be phased throughout the year. It is estimated that the expansion will create 36 new jobs at the site, which the company acquired in October 2017.
The 15,000-ft2expansion of the facility will include five new packaging suites and a new quality control laboratory. New equipment will include both a semi-automated and fully-automated top loading cartoner, an accessorized combination syringe assembly machine, an automated auto-injector assembly machine, and two semi-automatic visual inspection machines.
The 875,000-ft2 biologics development and manufacturing facility in Bloomington employs 900 staff. The site recently achieved regulatory approval for a twentieth commercial product and has expertise in sterile formulation and extensive biomanufacturing and drug product fill/finish capacity across liquid and lyophilized vials, prefilled syringes, and cartridges.
Source: Catalent Pharma Solutions